AstraZeneca PLC has unveiled third-quarter results Nov. 9 which were in line with expectations and also focused on the advances its cancer treatments have been making in the clinic and commercially.
AZ Confident New Cancer Drugs Can Drive Return To Sales Growth
The drugs major is looking to return to sales growth in 2018 and believes that its oncology division will be the main driver as the last wave of patent expiries ebbs away.
More from Earnings
• By
On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.